XenoPort Inc (XNPT) and GlaxoSmithkline Plc (GSK) Thursday jointly announced that the U.S. Food and Drug Administration, or the FDA, has granted approval for the Horizant Extended Release Tablets for the management of postherpetic neuralgia, or PHN, in adults.
XenoPort stated that the efficacy and safety of Horizant for the management of PHN was evaluated in a single 12-week principal efficacy trial, plus two supportive studies that all met their respective primary endpoints. The three clinical studies involved 574 adult patients from the US, Canada and Germany.
XenoPort further stated that it is entitled to receive a milestone payment of $10 million from GSK in association with GSK's first commercial sale of the product after approval for PHN,
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.